MacroGenics, Inc. Hits New 52-Week High of $4.93, Marking Significant Milestone

MacroGenics, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 4.93 on June 23, 2026. This achievement marks a notable increase from its 52-week low of USD 1.19, reflecting a substantial upward movement in the stock's performance over the past year. Despite a modest one-year performance of 2.4%, which lags behind the S&P 500's 22.24%, MacroGenics continues to navigate the competitive landscape of its industry. The company's market capitalization stands at USD 186 million, indicating its microcap status. Financial metrics reveal a challenging environment, with a negative return on equity of -134.23% and a debt-to-equity ratio of -2.06, suggesting a complex financial structure. As MacroGenics continues to operate within the dynamic pharmaceuticals and biotechnology sector, the recent achievement of its 52-week high underscores the stock's notable activity and the evolving market conditions surrounding it.